849917-35-7

Upstream product

• 141404-09-3 (3R,5R)-3,5-bis<(tert-butyldimethylsilyl)oxy>-4-<(trimethylsilyl)oxy>cyclohexanone 
• 681830-90-0 3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[(trimethylsilyl)oxy]cyclohexanol 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 
• 681433-63-6 (3R,5R)-3,5-bis-[(t-butyldimethylsilyl)oxy]-4-methylene-cyclohexanol benzyl ether 
• 681830-92-2 2,6-bis-[(tert-butyldimethylsilyl)oxy]-4-(benzyloxy)cyclohexanol 
• 681433-62-5 (2R,6R)-2,6-bis-[(tert-butyldimethylsilyl)oxy]-4-(benzyloxy)cyclohexanone 
• 100-39-0 benzyl bromide 

Downstream Products

• 681831-04-9 4-benzyloxy-2,6-bis-(tert-butyldimethylsilyloxy)-1-methylcyclohexanol 

Relevant academic research and scientific papers

New derivatives of 1α,25-dihydroxy-19-norvitamin D3 with two substituents at C-2: Synthesis and biological activity

To examine the effect of 2,2-disubstitution on the biological activities of 19-norvitamin D analogs, novel 2,2-disubstituted-(20R)- and (20S)-1α,25-dihydroxy-19-norvitamin D3 analogs were prepared and their biological activities were studied. A

2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE

An object of the present invention is to provide a novel 2,2-disubstituted-19-norvitamin D derivative. According to the present invention, there is provided a compound represented by the general formula (I): (wherein, R1 and R2 may be the same or differen